Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients
NCT07085117 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5
Last updated 2025-09-08
Summary
The main objective of this study is to assess the number of participants with proptosis response as of last intravenous infusion of teprotumumab.
Conditions
- Thyroid Eye Disease
Interventions
- DRUG
-
Teprotumumab
Participants received teprotumumab as an intravenous (IV) infusion.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
MD · Amgen
Eligibility
- Min Age
- 18 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-07-02
- Primary Completion
- 2025-08-10
- Completion
- 2025-08-10
- FDA Drug
- Yes
Countries
- China
Study Locations
More Related Trials
-
Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease
NCT04040894 ·Status: APPROVED_FOR_MARKETING
-
A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease
NCT05015127 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease
NCT06126783 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
NCT07152392 ·Status: RECRUITING ·Phase: PHASE4
-
Thyroid Treatment Trial
NCT00348413 ·Status: COMPLETED ·Phase: NA
-
The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
NCT07152340 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.
NCT07152366 ·Status: RECRUITING ·Phase: PHASE4
-
Thyroid Associated Orbitopathy Treatment by Methotrexate Against Triamcinolone Periocular Injections
NCT05429450 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease
NCT07308964 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
NCT07211776 ·Status: RECRUITING ·Phase: PHASE3
-
Multi-model Image of Doxycycline in TAO
NCT05112211 ·Status: RECRUITING ·Phase: NA
-
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
NCT06569758 ·Status: RECRUITING ·Phase: PHASE1
-
MHB018A Treatment in Patients With Chronic Thyroid Eye Disease
NCT07257185 ·Status: RECRUITING ·Phase: PHASE3
-
99Tc-MDP for Thyroid-Associated Ophthalmopathy
NCT03948191 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease
NCT06389578 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Study of Hyperthyroidism in Children
NCT06570967 ·Status: RECRUITING
-
A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease
NCT01114503 ·Status: TERMINATED ·Phase: PHASE2
-
A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
NCT04583735 ·Status: COMPLETED ·Phase: PHASE4
-
Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.
NCT05532072 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Construction and Application of Precise Diagnosis and Treatment System for Thyroid-associated Ophthalmopathy
NCT07124572 ·Status: RECRUITING
-
Thyroid Replacement Therapy in Patients With Subclinical Hypothyroidism
NCT04953195 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy
NCT06269393 ·Status: COMPLETED ·Phase: PHASE3
-
rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter
NCT00275171 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy
NCT00424151 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
NCT00389441 ·Status: COMPLETED ·Phase: PHASE2